Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
1.310
+0.170 (14.91%)
At close: May 12, 2025, 4:00 PM
1.308
-0.002 (-0.12%)
After-hours: May 12, 2025, 4:25 PM EDT
Tango Therapeutics Revenue
Tango Therapeutics had revenue of $5.39M in the quarter ending March 31, 2025, a decrease of -16.67%. This brings the company's revenue in the last twelve months to $40.99M, up 10.09% year-over-year. In the year 2024, Tango Therapeutics had annual revenue of $42.07M with 15.17% growth.
Revenue (ttm)
$40.99M
Revenue Growth
+10.09%
P/S Ratio
3.51
Revenue / Employee
$264,452
Employees
155
Market Cap
141.62M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
TNGX News
- 12 hours ago - Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewsWire
- 11 days ago - Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - GlobeNewsWire
- 6 weeks ago - Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 - GlobeNewsWire
- 2 months ago - Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights - GlobeNewsWire
- 3 months ago - Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference - GlobeNewsWire
- 3 months ago - Tango Therapeutics: Chance For A Short Squeeze - Seeking Alpha
- 5 months ago - Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 months ago - Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference - Business Wire